Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis

Published:2020-07-28 Issue:10 Volume:14 Page:1027-1043
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Gaikwad Archana Vijay¹,Eapen Mathew Suji¹,McAlinden Kielan D.¹,Chia Collin¹²,Larby Josie¹²,Myers Stephen¹,Dey Surajit¹,Haug Greg¹²,Markos James¹²,Glanville Allan R.³,Sohal Sukhwinder Singh¹

Affiliation:

1. Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia

2. Department of Respiratory Medicine, Launceston General Hospital, Launceston, Australia

3. Lung Transplant Unit, Department of Thoracic Medicine, St Vincent’s Hospital, Sydney, Australia

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2020.1795832

Reference217 articles.

1. The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases

2. CLINICAL-PATHOLOGICAL CONFERENCE

3. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic investigation of wogonin in delaying the progression of endothelial mesenchymal transition by targeting the TGF-β1 pathway in pulmonary hypertension;European Journal of Pharmacology;2024-09

2. TGFβ1, SMAD and β-catenin in pulmonary arteries of smokers, patients with small airway disease and COPD: potential drivers of EndMT;Clinical Science;2024-08-28

3. Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation;Acta Pharmaceutica Sinica B;2024-08

4. Network pharmacology and experimental verification to decode the action of Qing Fei Hua Xian Decotion against pulmonary fibrosis;PLOS ONE;2024-06-24

5. SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives;Critical Reviews in Clinical Laboratory Sciences;2024-06-07